Tharimmune, Inc. | Finanzwire

Basculer en Français

9473	Companies
185416	Keywords
117771	Articles
99291	Press releases

Home
Companies
Tharimmune, Inc.

BRIEF

published on 11/13/2024 at 14:05, 1 year ago

Tharimmune Secures European Patent for Innovative Cancer Therapy Platform

Drug Delivery Tharimmune European Patent Cancer Therapies Biodegradable Nanoparticles
PRESS RELEASE

published on 11/13/2024 at 14:00, 1 year ago

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Tharimmune, Inc. announces the European Patent Office intends to grant a patent for biodegradable polymeric nanoparticles designed to enhance therapeutic delivery in cancer therapies. The innovative platform aims to reduce side effects and improve therapy effectiveness

Patent Tharimmune Cancer Therapies Nanoparticles Therapeutic Delivery
BRIEF

published on 11/04/2024 at 15:05, 1 year 1 month ago

Tharimmune Announces Participation in Upcoming Conferences

Biotechnology TH104 Investor Meetings Tharimmune Conference Participation
PRESS RELEASE

published on 11/04/2024 at 15:00, 1 year 1 month ago

Tharimmune Announces Upcoming Conference Presentations
Tharimmune, Inc. announces participation in 2024 Spartan Capital Investor Conference and AASLD The Liver Meeting® 2024. Details on upcoming events and key developments in biotechnology

Biotechnology Tharimmune Inc. Clinical-stage Inflammation Immunology
BRIEF

published on 10/30/2024 at 13:05, 1 year 1 month ago

Tharimmune Secures EMA Feedback for TH104 in Chronic Pruritus

Chronic Pruritus Tharimmune PBC Treatment EMA Feedback TH104 Clinical Program
PRESS RELEASE

published on 10/30/2024 at 13:00, 1 year 1 month ago

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. receives positive feedback from EMA on Phase 2 trial plans for TH104, a clinical candidate for pruritus in PBC, a rare liver disease

Tharimmune Inc. Phase 2 Trial PBC Pruritus European Medicines Agency
BRIEF

published on 10/28/2024 at 14:05, 1 year 1 month ago

Tharimmune Reports Positive Phase 1 Results for TH104 at ACG Meeting

TH104 Phase 1 Trial Pruritus Chronic Liver Disease Clinical Safety
PRESS RELEASE

published on 10/28/2024 at 14:00, 1 year 1 month ago

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
Tharimmune presents positive Phase 1 data for TH104 in treating pruritus in chronic liver disease patients at ACG 2024. No opioid withdrawal effects observed, supporting safety profile

TH104 Tharimmune Pruritus Chronic Liver Disease Phase 1 Data
BRIEF

published on 10/25/2024 at 14:05, 1 year 1 month ago

Tharimmune to Present Key Findings at Upcoming Conferences

Biotechnology Conference Therapeutics Tharimmune Immunology
PRESS RELEASE

published on 10/25/2024 at 14:00, 1 year 1 month ago

Tharimmune Announces Upcoming Conference Presentations
Tharimmune, Inc. to present new results from Phase 1 trial of TH104 at ACG 2024 Annual Scientific Meeting. CEO to speak at 2024 ThinkEquity Conference in NY. Webcast available

Tharimmune Inc. Phase 1 Trial Clinical-stage Biotechnology ACG 2024 ThinkEquity Conference

Accesswire

Published on 12/05/2025 at 02:35, 7 hours 10 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 7 hours 15 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 8 hours 45 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 40 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 45 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 09:30, 15 minutes ago

REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 39 minutes ago

Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 44 minutes ago

Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 09:00, 45 minutes ago

SPECTRIS PLC - Removal
Published on 12/05/2025 at 09:00, 45 minutes ago

Official List Notice

Les Echos

Published on 12/05/2025 at 08:45, 1 hour ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 15 hours 45 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 16 hours ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 16 hours ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 2 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE